PFM Health Sciences’s Prothena Corp PRTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-189,744
Closed -$6.9M 88
2023
Q4
$6.9M Sell
189,744
-646,827
-77% -$24.9M 0.41% 50
2023
Q3
$40.4M Buy
836,571
+62,025
+8% +$3.68M 1.9% 22
2023
Q2
$52.9M Hold
774,546
2.05% 16
2023
Q1
$37.5M Sell
774,546
-100,918
-12% -$5.33M 1.66% 26
2022
Q4
$52.7M Buy
875,464
+35,226
+4% +$2.06M 1.89% 15
2022
Q3
$50.9M Buy
840,238
+495,124
+143% +$15.7M 1.84% 15
2022
Q2
$9.37M Buy
+345,114
New +$10.1M 0.36% 61
2014
Q2
Sell
-541,983
Closed -$20.8M 75
2014
Q1
$20.8M Buy
+541,983
New +$17.5M 0.38% 52

Other funds holding PRTA

PFM Health Sciences's PRTA Position: Q1 2024 in Review

PFM Health Sciences sold out of Prothena Corp (PRTA) in Q1 2024, closing a stake of 189,744 shares — an estimated $6.9M sold.

PFM Health Sciences first reported a position in PRTA in Q1 2014 and held it in 8 quarters. The position peaked at $52.9M in Q2 2023. 169 funds tracked by Wall St. Rank hold PRTA as of Q1 2024.

  • PFM Health Sciences reported no remaining Prothena Corp position as of Q1 2024 after selling out during the quarter.
  • PFM Health Sciences sold 189,744 Prothena Corp shares in Q1 2024, an estimated $6.9M.
  • PFM Health Sciences first reported a position in Prothena Corp in Q1 2014 and held it in 8 quarters.
  • PFM Health Sciences's Prothena Corp position peaked at $52.9M in Q2 2023.
  • 169 funds tracked by Wall St. Rank held Prothena Corp as of Q1 2024.

Based on PFM Health Sciences's 13F filing for Q1 2024, filed 14 May 2024.